EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
EQRx, a pharmaceutical company focused on providing innovative medicines for conditions like cancer and immune-inflammatory diseases, announced its participation in the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
EQRx, a pharmaceutical company focused on providing innovative medicines for conditions like cancer and immune-inflammatory diseases, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 4:30 p.m. PST / 7:30 p.m. EST. The event will include a live and archived webcast accessible via the company’s website. Since its launch in January 2020, EQRx has aimed to enhance access to medicines through advanced science and strategic collaborations.
Details
News Market Reaction – EQRX
The recorded move for EQRX in the trading session of this news was +1.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 4:30 p.m. PST / 7:30 p.m. EST.
A live and archived webcast of the presentation will be available by visiting the News & Events section of EQRx’s website, and selecting Events & Presentations, at investors.eqrx.com.
About EQRx
EQRx is a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions. Launched in January 2020, EQRx is leveraging cutting-edge science, technology and strategic partnerships with stakeholders from across the healthcare system toward the goal of increasing access for patients around the world. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRx_US, LinkedIn, Instagram: @eqrxinc.
EQRx™ and Remaking Medicine™ are trademarks of EQRx.
EQRx Contacts:
Media:
Dan Budwick
1AB
dan@1abmedia.com
Investors:
investors@eqrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.